BioNexus Gene Lab Stock (NASDAQ:BGLC)


RevenueOwnershipFinancialsChart

Previous Close

$1.97

52W Range

$1.07 - $15.60

50D Avg

$2.16

200D Avg

$3.56

Market Cap

$4.24M

Avg Vol (3M)

$90.55K

Beta

2.19

Div Yield

-

BGLC Company Profile


BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

MY

Employees

30

IPO Date

Jan 08, 2021

Website

BGLC Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceSep 25Jun 25
Product And Service$2.54M$2.26M

Fiscal year ends in Dec 25 | Currency in USD

BGLC Financial Summary


Dec 25Dec 24Dec 23
Revenue$7.42M$9.51M$9.77M
Operating Income$-2.97M$-1.57M$-2.59M
Net Income$-2.98M$-1.60M$-2.63M
EBITDA$-2.97M$-1.42M$-2.49M
Basic EPS$-1.61$-0.90$-1.53
Diluted EPS$-1.61$-0.90$-1.53

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison


TickerCompany
APMAptorum Group Limited
ADVBAdvanced Biomed Inc. Common Stock
LFWDLifeward Ltd.
LYRALyra Therapeutics, Inc.
XAIRBeyond Air, Inc.
GLTOGalecto, Inc.
MBIOMustang Bio, Inc.
TRIBTrinity Biotech plc